Exelixis
EXEL
$22.70
Share price
-0.48%
Change (1 day)
14.94%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Revenue for Exelixis (EXEL)
Revenue in 2023 (TTM): $1.83 B
According to Exelixis's latest financial reports the company's current revenue (TTM) is $1.83 B. In 2022 the company made a revenue of $1.61 B an increase over the years 2021 revenue that were of $1.43 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exelixis from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $1.83 B | 13.6% |
| 2022 | $1.61 B | 12.27% |
| 2021 | $1.43 B | 45.31% |
| 2020 | $0.98 B | 2.04% |
| 2019 | $0.96 B | 13.35% |
| 2018 | $0.85 B | 88.7% |
| 2017 | $0.45 B | 136.34% |
| 2016 | $0.19 B | 415.05% |
| 2015 | $37.17 M | 48.03% |
| 2014 | $25.11 M | -19.87% |
| 2013 | $31.33 M | -33.96% |
| 2012 | $47.45 M | -83.62% |
| 2011 | $0.28 B | 56.52% |
| 2010 | $0.18 B | 21.93% |
| 2009 | $0.15 B | 28.76% |
| 2008 | $0.11 B | 3.87% |
| 2007 | $0.11 B | 15% |
| 2006 | $98.67 M | 29.9% |
| 2005 | $75.96 M | 43.71% |
| 2004 | $52.85 M | 2.56% |
| 2003 | $51.54 M | 16.29% |
| 2002 | $44.32 M | 8.09% |
| 2001 | $41 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $93.02 B | 4,982.59% | 🇺🇸 USA |
 Pfizer PFE | $58.49 B | 3,096.19% | 🇺🇸 USA |
 Amgen AMGN | $28.19 B | 1,440.26% | 🇺🇸 USA |
 Sanofi SNY | $50.35 B | 2,651.60% | 🇫🇷 France |
 Merck MRK | $60.11 B | 3,184.54% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $45.00 B | 2,359.06% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $37.84 B | 1,968.02% | 🇬🇧 UK |
 Curis CRIS | $10.02 M | -99.45% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $94.31 M | -94.85% | 🇺🇸 USA |